Telacebec will be developed to treat tuberculosis and few non-tuberculosis mycobacteria infections. Credit: Department of Pathology, Calicut Medical college / Wikimedia.

South Korean biotechnology company Qurient has entered a licence agreement with TB Alliance for the development and commercialisation of telacebec (Q203).

Under the deal, TB Alliance will have the exclusive global license to develop and market telacebec except in Russia, South Korea, and the Commonwealth of Independent States (CIS) countries.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The first-in-class orally available investigational drug, Telacebec blocks Mycobacterium tuberculosis growth by inhibiting cytochrome bc1 complex.

It will be developed to treat tuberculosis (TB) and other non-tuberculosis mycobacteria (NTM) infections.

In preclinical and clinical studies, the drug showed potent efficacy against drug-sensitive and drug-resistant TB.

It was successfully evaluated in Phase IIa early bactericidal activity (EBA) study for the treatment of TB.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In March 2020, the findings from the trial were published in the New England Journal of Medicine.

Qurient CEO Kiyean Nam said: “As telacebec’s unique mechanism of action of blocking energy metabolism of the Mycobacterium can address all types of TB, including drug-resistant TB, we expect telacebec to potentially become an essential component of drug combination regimens for the treatment of TB.

“We believe telacebec will greatly contribute to the global efforts to combating the TB pandemic, which remains a serious public health challenge worldwide.

“Our partnership with the TB Alliance will accelerate the widespread availability of telacebec and bring it to those in need.”

The US Food and Drug Administration (FDA) has granted Fast Track Designation and Orphan Drug Designation to telacebec.

The drug was also found to be effective against buruli ulcer (Mycobacterium ulcerans), a chronic, necrotising disease that affects the skin and sometimes bone.

TB Alliance president and CEO Mel Spigelman said: “New drugs like telacebec are urgently needed in the fight against TB as well as certain NTM infections – compounds with potentially impactful novel mechanisms of action can have a significant benefit in combating the TB pandemic.

“We look forward to advancing this new compound as part of combination regimens that could yield a short, simple, safe, and highly effective cure for all forms of TB.”